Gadolinium contrast

PreclinicalSmall molecule

WWashington University School of Medicine

Gadolinium contrast is one of 14 small molecule programs targeting Neurofibromatosis Type 1. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neurofibromatosis Type 1Active, not recruiting

Neurofibromatosis Type 1Preclinical

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Neurofibromatosis Type 1

#DrugCompanyPhaseTrials

Ritalin

Novartis

Approved

1 2

Verzenio

Eli Lilly

Approved

—3

Levulan

Sun Pharmaceutical Industries, Inc.

Afinitor

Lamictal

GGlaxo Dba Glaxosmithkline

Approved

—6

Celebrex

PPhiladelphia Eye Associates

Approved

—7

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—8

Acetadote

AArbor Pharmaceuticals, Inc.

Koselugo

2 10

N-Acetyl Cyteien

SStanford University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Brain Injury1 trial

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

Terminated·UUniformed Services University of the Health Sciences·Phase 2·NCT04058132·1 enrolled

Neurofibromatosis Type 11 trial

Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma

Terminated·WWashington University School of Medicine·N/A·NCT02584413·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Gadolinium contrast. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gadolinium contrast compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gadolinium contrast. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWashington University School of Medicine

Gadolinium contrast

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Brain Injury1 trial

Neurofibromatosis Type 11 trial

References

Drug Info

Quick Facts

Related News